Receptor-mimic probiotics: Potential therapeutics for bacterial toxin-mediated enteric diseases

Expert Review of Gastroenterology and Hepatology

Volumn 4, Issue 3, 2010, Pages 253-255

  Paton, Adrienne W ^a   Morona, Renato ^a   Paton, James C ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL TOXIN; GLYCOSYLTRANSFERASE; HEAT LABILE ENTEROTOXIN; OLIGOSACCHARIDE; PROBIOTIC AGENT; SHIGA TOXIN; UNCLASSIFIED DRUG; CELL SURFACE RECEPTOR;

ABDOMINAL PAIN; BACTERIAL OUTER MEMBRANE; CAMPYLOBACTER JEJUNI; CHOLERA; DIARRHEA; EDITORIAL; ENTEROTOXIGENIC ESCHERICHIA COLI; ESCHERICHIA COLI INFECTION; FOOD CONTAMINATION; GASTROINTESTINAL DISEASE; HEMORRHAGIC COLITIS; HUMAN; INTESTINE FLORA; NEISSERIA; NONHUMAN; SHIGA TOXIN PRODUCING ESCHERICHIA COLI; VIBRIO CHOLERAE; ANTAGONISTS AND INHIBITORS; BACTERIAL INFECTION; COMPLICATION; GASTROINTESTINAL DISEASES; METABOLISM; MOLECULAR MIMICRY;

BACTERIAL INFECTIONS; BACTERIAL TOXINS; GASTROINTESTINAL DISEASES; HUMANS; MOLECULAR MIMICRY; PROBIOTICS; RECEPTORS, CELL SURFACE;

EID: 77953250931     PISSN: 17474124     EISSN: None     Source Type: Journal    
DOI: 10.1586/egh.10.30     Document Type: Editorial

References (11)

1. Fan E, Merritt EA, Verlinde CL, Hol WGJ. AB5 toxins: structures and inhibitor design. Curr. Opin. Struct. Biol. 10, 680-686 (2000).
2. Kitov PI, Sadowska JM, Mulvey G et al. Shiga-like toxins are neutralized by tailored multivalent carbohydrate ligands. Nature 403, 669-672 (2000).
3. Merritt EA, Zhang Z, Pickens JC, Ahn M, Hol WG, Fan E. Characterization and crystal structure of a high-affinity pentavalent receptor-binding inhibitor for cholera toxin and E. coli heat labile enterotoxin. J. Am. Chem. Soc. 124, 8818-8824 (2002).
4. Nishikawa K, Matsuoka K, Watanabe M et al. Identification of the optimal structure required for a Shiga toxin neutralizer with oriented carbohydrates to function in the circulation. J. Infect. Dis. 191, 2097-2105 (2005).
5. Kitov PI, Mulvey GL, Griener TP et al. In vivo supramolecular templating enhances the activity of multivalent ligands: a potential therapeutic against the Escherichia coli O157 AB5 toxins. Proc. Natl Acad. Sci. USA 105, 16837-16842 (2008).
6. Paton AW, Morona R, Paton JC. Designer probiotics for prevention of enteric infections. Nat. Rev. Microbiol. 4, 193-200 (2006).
7. Paton AW, Morona R, Paton JC. A new biological agent for treatment of Shiga toxigenic Escherichia coli infections and dysentery in humans. Nat. Med. 6, 265-270 (2000).
8. Paton AW, Morona R, Paton JC. Neutralization of Shiga toxins Stx1, Stx2c and Stx2e by recombinant bacteria expressing mimics of globotriose and globotetraose. Infect. Immun. 69, 1967-1970 (2001).
9. Paton AW, Jennings MP, Morona R, Focareta A, Roddam LF, Paton JC. Recombinant probiotics for treatment and prevention of travellers' diarrhea. Gastroenterology 128, 1219-1228 (2005).
10. Focareta A, Paton JC, Morona R, Cook J, Paton AW. A recombinant probiotic for treatment and prevention of cholera. Gastroenterology 130, 1688-1695 (2006).
11. Paton JC, Rogers TJ, Morona R, Paton AW. Oral administration of formalin-killed recombinant bacteria expressing a mimic of the Shiga toxin receptor protects mice from fatal challenge with Shiga toxigenic Escherichia coli. Infect. Immun. 69, 1389-1393 (2001).